A crucial role of interleukin-6 in the pathogenesis of thyroxicosis-related disturbances of bone turnover in mice

Hormone and Metabolic Research

Volumn 39, Issue 12, 2007, Pages 884-888

  Mysliwlec, J ^a   Zbucki, R ^a   Winnicka, M M ^a   Sawicki, B ^a   Nikolajuk, A ^a   Kaminski, K ^a   Mysliwiec, P ^a   Musial, W ^a   Bondyra, Z ^a   Walecki, J ^a   Gorska, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Hyperthyreosis; IL 6; IL 6 knock out mice; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; BIOLOGICAL MARKER; CREATININE; INTERLEUKIN 6; LEVOTHYROXINE; OSTEOCALCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE TURNOVER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; HYPERTHYROIDISM; KNOCKOUT MOUSE; METABOLIC BONE DISEASE; MOUSE; NONHUMAN; OSSIFICATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THYROTOXICOSIS; WILD TYPE;

ACID PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES; DENSITOMETRY; FEMALE; GENOTYPE; INTERLEUKIN-6; ISOENZYMES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOCALCIN; THYROID GLAND; THYROTOXICOSIS;

ANIMALIA; MUS;

EID: 38149017211     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992776     Document Type: Article

References (33)

1. Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61: 466-472
2. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16249 patients. Thyroid 2002; 12: 411-419
3. Baldini M, Gallazzi M, Orsatti A, Fossati S, Leonardi P, Cantalamessa L. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med 2002; 251: 407-414
4. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999; 84: 435-439
5. Takai S, Tokuda H, Hanai Y, Kozawa O. Phosphatidylinositol 3-kinase/Akt plays a part in Tumor Necrosis Factor α induced interleukin-6 synthesis in osteoblasts. Horm Metab Res 2006; 38: 563-569
6. Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. Q J Med 2002; 95: 233-240
7. Sanchez MC, Bajo MA, Selgas R, Mate A, Sanchez-Cabezudo MJ, Lopez-Barea F, Esbrit P, Martinez ME. Cultures of human osteoblastic cells from dialysis patients: influence of bone turnover rate on in vitro selection of interleukin-6 and osteoblastic cell makers. Am J Kidney Dis 2001; 37: 30-37
8. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C- reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003; 88: 255-259
9. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13: 1189-1196
10. Hayashi M, Rho MC, Enomoto A, Fukami A, Kim YP, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci USA 2002; 12: 14728-14733
11. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 2005; 289: E784-E793
12. Siddiqi A, Burrin JM, Wood DF, Monson JP. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells. J Endocrinol 1998; 157: 453-461
13. Kim CH, Kim HK, Shong YK. Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: a possible mediator of thyroid hormone-induced bone loss. J Endocrinol 1999; 160: 97-102
14. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I, Tarjan G, Stern PH. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997; 82: 78-81
15. Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf) 2002; 57: 125-129
16. Fujikawa M, Kamihira K, Sato K, Okamura K, Kidota S, Lida M. Elevated bone resorption markers in a patient with hypercalcemia associated with post-partum thyrotoxicosis and hypoadrenocorticism due to pituitary failure. J Endocrinol Invest 2004; 27: 782-787
17. Pantazi H, Papapetrou PD. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1099-1106
18. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effect of treatment. J Clin Endocrinol Metab 1994; 78: 955-959
19. Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrinol 2004; 61: 285-298
20. Williams GR, Bland R, Sheppard MC. Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling. Endocrinology 1994; 135: 2375-2385
21. Pereira RC, Jorgetti V, Canalis E. Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts. Am J Physiol Endocrinol Metab 1999; 277: E496-E504
22. Stevens DA, Harvey CB, Scott AJ, O'Shea PJ, Barnard JC, Williams AJ, Brady G, Samarut J, Chassande O, Williams GR. Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone. Mol Endocrinol 2003; 17: 1751-1766
23. Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 2003; 213: 1-11
24. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodelling. N Engl J Med 1995; 332: 305-311
25. Hallen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaannen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-1345
26. Marshall K, Nash K, Haussman G, Cassady I, Hume D, Jersey J de, Hamilton S. Recombinant human and mouse purple acid phosphatases: expression and characterization. Arch Biochem Biophys 1997; 345: 230-236
27. 3 or parathyroid hormone. J Biol Chem 1999; 274: 19301-19308
28. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T. Regulation of Matrix Metalloproteinases (MMP-2, -3, -9, and -13) by Interleukin-1 and Interieukin-6 in Mouse Calvaria: Association of MMP Induction with Bone Resorption. Endocrinology 1998; 139: 1338-1345
29. Varga F, Spitzer S, Rumpler M, Klaushofer K. 1,25-Dihydroxyvitamin D3 inhibits thyroid hormone-induced osteocalcin expression in mouse osteoblast-like cells via a thyroid hormone response element. J Mol Endocrinol 2003; 30: 49-57
30. Li YP, Stashenko P. Proinflammatory cytokines tumor necrosis factor-α and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. J Immunol 1992; 148: 788-794
31. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002; 298: 843-846
32. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004; 113: 379-389
33. Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann N Y Acad Sci 2006; 1068: 225-233